Clinical Performance Study Plan Development Services

A clinical performance study plan is a structured document that explains how a manufacturer will generate and evaluate clinical performance data for a device, especially an IVD. It typically defines the study objective, intended population, endpoints, methodology, statistical approach, data management, monitoring, and documentation controls. The plan helps ensure the study is scientifically sound, operationally clear, and suitable for regulatory review.

A clinical study plan is the roadmap for conducting a clinical investigation or performance study. It outlines why the study is being done, what evidence will be collected, how subjects or samples will be selected, what procedures will be followed, and how results will be analyzed. In regulated industries, it also supports compliance, traceability, and consistency across teams, sites, and submission documents.

The protocol is the core operational and scientific document for a clinical study. It describes the study design, objectives, eligibility criteria, procedures, endpoints, monitoring methods, safety considerations, and statistical analysis plan. In practice, the protocol must be detailed enough for investigators, sponsors, and reviewers to understand exactly how the study will be conducted and how the resulting data will support regulatory or clinical claims.

A well-developed study plan helps regulators see that the evidence generation approach is intentional, traceable, and aligned with the device's intended use and claims. It reduces the risk of unclear endpoints, weak methodology, inconsistent data collection, or missing documentation. Strong planning also improves internal execution by aligning clinical, regulatory, quality, and biostatistics teams before the study begins.

A complete plan usually includes study objectives, rationale, intended use context, endpoints, study design, inclusion and exclusion criteria, sample strategy, data collection methods, monitoring approach, statistical considerations, risk controls, and documentation responsibilities. Depending on the device and market, it may also address GCP alignment, data integrity expectations, adverse event handling, and links to broader clinical evidence or performance evaluation requirements.

Elexes supports manufacturers by drafting or reviewing study plans, aligning them with applicable regulatory frameworks, and ensuring the documentation is coherent, defensible, and submission-ready. The team helps define objectives, endpoints, methodology, and evidence strategy while checking for consistency with risk management, intended use, and broader regulatory documentation. This reduces avoidable gaps before study execution or authority review.

Yes. Elexes supports study planning in the context of IVDR, FDA, TGA, Health Canada, and other global frameworks where clinical or performance evidence is required. The goal is to build a plan that is not only scientifically appropriate but also usable within the target submission pathway. That includes documentation structure, evidence traceability, and alignment with related technical and quality records.

The study plan should be developed before study execution begins and ideally early enough to influence evidence strategy, resource planning, and regulatory decision-making. Starting early allows teams to identify data gaps, refine endpoints, confirm feasibility, and align internal stakeholders. It also helps avoid protocol amendments, duplicated work, and evidence packages that fail to support the intended submission or market access strategy.